Evidence map›Paper›PMID 35817279›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2022

Indocarbocyanine nanoparticles extravasate and distribute better than liposomes in brain tumors.

Irina V Balyasnikova, Markella Zannikou, Guankui Wang, Yue Li, Joseph T Duffy, Rebecca N Levine, Maggie Seblani, Hanmant Gaikwad, Dmitri Simberg

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Harnessing Organoid Platforms for Nanoparticle Drug Development.Drug design, development and therapy · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Irina V BalyasnikovaDepartment of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Electronic address: irinabal@northwestern.edu.
Markella ZannikouDepartment of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Guankui WangDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, USA; Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Yue LiDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, USA; Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Joseph T DuffyDepartment of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Rebecca N LevineDepartment of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Maggie SeblaniDepartment of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
Hanmant GaikwadDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, USA; Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Dmitri SimbergDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, USA; Colorado Center for Nanomedicine and Nanosafety, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: dmitri.simberg@cuanschutz.edu.
University of Colorado Anschutz Medical Campus · USNorthwestern University · USNeurological Surgery · USNorthwestern Medicine · US

Funding

The Alternative Complement Pathway and Hemocompatibility of NanosurfacesR01AI154959 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Dmitri Simberg · 2020 to 2026
$3.5M
Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive GlioblastomaR01CA257958 · NCI · UNIVERSITY OF COLORADO DENVER · PI Irina V Balyasnikova, Dmitri Simberg · 2022 to 2026
$2.7M
Genetic Approaches to Optimize CAR T cells for Glioblastoma TherapyR01NS106379 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V, GOTTSCHALK, STEPHEN · 2018 to 2022
$2.7M
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBMR01NS122395 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BALYASNIKOVA, IRINA V · 2021 to 2025
$1.9M
Targeting SEC61 complex to overcome resistance to immunotherapy in GBMR01CA290737 · NCI · NORTHWESTERN UNIVERSITY · PI Irina V Balyasnikova · 2025 to 2026
$1.2M
NCI NIH HHS R01 CA257958NCI NIH HHS R01 CA290737NIAID NIH HHS R01 AI154959NINDS NIH HHS R01 NS106379NINDS NIH HHS R01 NS122395
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most devastating and aggressive brain tumor in adults. Hidden behind the blood-brain and blood-tumor barriers (BBTB), this invasive type of brain tumor is not readily accessible to nano-sized particles. Here we demonstrate that fluorescent indocarbocyanine lipids (ICLs: DiD, DiI) formulated in PEGylated lipid nanoparticle (PLN) exhibit highly efficient penetration and accumulation in GBM. PLN-formulated ICLs demonstrated more efficient penetration in GBM spheroids and organoids in vitro than liposomal ICLs. Over 82% of the tumor's extravascular area was positive for ICL fluorescence in the PLN group versus 13% in the liposomal group just one hour post-systemic injection in the intracranial GBM model. Forty-eight hours post-injection, PLN-formulated ICLs accumulated in 95% of tumor myeloid-derived suppressor cells and macrophages, 70% of tumor regulatory T cells, 50% of tumor-associated microglia, and 65% of non-immune cells. PLN-formulated ICLs extravasated better than PEGylated liposomal doxorubicin and fluorescent dextran and efficiently accumulated in invasive tumor margins and brain-invading cells. While liposomes were stable in serum in vitro and in vivo, PLNs disassembled before entering tumors, which could explain the differences in their extravasation efficiency. These findings offer an opportunity to improve therapeutic cargo delivery to invasive GBM.

Indexed as

Brain NeoplasmsGlioblastomaNanoparticlesCell Line, TumorDextransHumansLipidsLiposomesPolyethylene GlycolsDextransLipid NanoparticlesLipidsLiposomesPolyethylene GlycolsFluorescenceGliomaInvasiveLipid nanoparticlesLiposomesPEG

Identifiers

PMID35817279
PMCPMC10200250
OpenAlexW4285078205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.